![]() Marcel Zwaal, Chief Executive Officer of Gadeta said, "Today, we are pleased to announce a significant milestone in the journey of Gadeta. This acquisition reaffirms our belief that Clade's engineerable platform provides the right 'chassis' for integrating compelling innovations coming out of the autologous cell therapy ecosystem." Clade's pipeline programs are focused on replicating the benefits of the autologous cell therapy products, while addressing their profound limitations - inconsistent quality, challenging patient logistics, and lack of scalability. Jim Glasheen, Ph.D., President and Chief Business Offer of Clade Therapeutics added, "Gadeta has generated compelling in-vitro and in-vivo data over the last few years with its lead gamma/delta (g/d) TCRs in solid tumor indications and we're excited to integrate this novel targeting into Clade's solid tumor programs. This integration seamlessly complements Clade's existing platform and commitment to developing engineerable, off-the-shelf, scalable, and consistent cell medicines." The acquisition of Gadeta represents a strategic move to integrate a third element to our platform: 'Universal Targeting'. "Our technology platform consists of both a 'Cell Foundry' that enables the generation of adult immune cells including both CD8+ and CD4+ T Cells, as well as a 'Cloaking Engine' that ensures best-in-class and tuned protection from both the cellular and humoral wings of a host's immune system. ![]() "Clade is at the forefront of broadening the impact of cell therapy by establishing a more robust cellular platform with stem-cell derived immune cells," said Chad Cowan, Ph.D., Chief Executive Officer of Clade Therapeutics. Gadeta shareholders will receive upfront and downstream economics. Under the terms of the acquisition agreement, Clade has acquired all outstanding shares of Gadeta, making it a wholly owned subsidiary of Clade. The integration of Gadeta's g/d TCR targeting technology is complementary to Clade's cellular platform technology and will enhance the development of engineerable, off-the-shelf, scalable, and consistent stem-cell based medicines. The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies. These g/d TCRs recognize unique patterns or targets on the surface of cancer cells that signal that they are diseased, thereby specifically targeting cancer cells and sparing healthy cells. The company developed a proprietary platform to engineer novel g/d TCRs that possess broad tumor targeting capabilities. Gadeta is an international R&D company, focused on innovative immunotherapies for cancer. ("Gadeta"), a cell therapy company developing innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients. 02, 2023 - Clade Therapeutics ("Clade"), a biopharmaceutical company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines, today announced that it has completed the acquisition of Gadeta B.V. g/d TCR candidate integrated into Clade's solid tumor pipelineīOSTON, Oct. ![]() proprietary gamma/delta (g/d) TCR universal targeting platform technology, Expands Clade's pipeline and broadens its platform with: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |